Posted by Adam Awdish on
Diptendu Chatterjee, Maurizio Pieroni, Meena Fatah, Flavien Charpentier, Kristopher S Cunningham, Danna A Spears, Dipashree Chatterjee, Gonca Suna, J Martjin Bos, Michael J Ackerman, Eric Schulze-Bahr, Sven Dittmann, Pasquale G Notarstefano, Leonardo Bolognese, Firat Duru, Ardan M Saguner, Robert M Hamilton
European Heart Journal
August 7, 2020
Brugada syndrome (BrS) is characterized by a unique electrocardiogram (ECG) pattern and life-threatening arrhythmias. However, the Type 1 Brugada ECG pattern is often transient, and a genetic cause is only identified in <25% of patients. This study sought to identify an additional biomarker for this rare condition. As myocardial inflammation may be present in BrS, researchers evaluated whether myocardial autoantibodies can be detected in these patients. A biomarker profile of autoantibodies against four cardiac proteins can be identified from sera of BrS patients and is highly sensitive and specific, irrespective of genetic cause for BrS. The four involved proteins are expressed abnormally in the myocardium of patients with BrS. This study used Single Donor Human Serum Off The Clot from Innovative Research as the control variable.
Related products available from Innovative Research also include: